A new study published in Nature highlights a major scientific milestone from LongeVC’s partner, Insilico Medicine. Using their generative AI drug discovery platform, Chemistry42, the team designed ISM3312, a novel, covalent inhibitor of the coronavirus main protease with broad-spectrum antiviral activity. The compound showed potent effects across multiple strains, including SARS-CoV-2, MERS-CoV, and common cold variants. Importantly, ISM3312 remained effective against treatment-resistant variants and can be administered orally, offering a significant advantage for pandemic response strategies.
This study underscores the real-world impact of AI in therapeutic development. Insilico CEO Alex Zhavoronkov, who also chairs LongeVC’s advisory board, continues to lead pioneering work in this space. Read the full paper in Nature.
This study underscores the real-world impact of AI in therapeutic development. Insilico CEO Alex Zhavoronkov, who also chairs LongeVC’s advisory board, continues to lead pioneering work in this space. Read the full paper in Nature.